Randomized trials to study the nonspecific effects of vaccines in children in low-income countries

Pediatric Infectious Disease Journal

Volumn 29, Issue 5, 2010, Pages 457-461

  Shann, Frank ^a   Nohynek, Hanna ^b   Scott, J Anthony ^c,d   Hesseling, Anneke ^e   Flanagan, Katie L ^f  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c Wellcome Trust/KEMRI Collaborative Programme   (Kenya)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

Immunologic memory; Mortality; Nonspecific effects; Randomized controlled trial; Vaccines

Indexed keywords

ALUMINUM; BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; MEASLES VACCINE;

CHILD HEALTH CARE; CHILDHOOD MORTALITY; CLINICAL TRIAL; DIPHTHERIA; DRUG SAFETY; EARLY INTERVENTION; HEALTH PROGRAM; HEPATITIS B; HUMAN; IMMUNIZATION; INFECTION RESISTANCE; LOWEST INCOME GROUP; MEASLES; MEDICAL LITERATURE; MEDICAL RESEARCH; METHODOLOGY; MORBIDITY; NOTE; OUTCOME ASSESSMENT; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESEARCH ETHICS; TETANUS; THERAPY DELAY; TUBERCULOSIS;

EID: 77951847316     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181c91361     Document Type: Article

References (34)

1. Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol. 2002;2:417-426.
2. Chen HD, Fraire AE, Joris I, et al. Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung. Am J Pathology. 2003;163:1341-1355.
3. Shann F. Heterologous immunity and the nonspecific effects of vaccines: a major medical advance? Pediatr Infect Dis J. 2004;23:555-558.
4. Selin LK, Brehm MA, Naumov YN, et al. Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol Rev. 2006;211:164-181.
5. Aaby P, Garly ML, Nielsen J, et al. Increased female-male mortality ratio associated with inactivated polio and diphtheria-tetanus-pertussis vaccines: observations from vaccination trials in Guinea-Bissau. Pediatr Infect Dis J. 2007;26:247-252.
6. Didierlaurent A, Goulding J, Hussell T. The impact of successive infections on the lung microenvironment. Immunology. 2007;122:457-465.
7. Roth A, Garly ML, Jensen H, et al. Bacillus Calmette-Guerin vaccination and infant mortality. Expert Rev Vaccines. 2006;5:277-293.
8. Aaby P, Jensen H. Do measles vaccines have non-specific effects on mortality. Bull WHO. 2005;83:238.
9. Aaby P, Garly ML, Bale C, et al. Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: an unplanned study. Pediatr Infect Dis J. 2003;22:798-805.
10. Benn CS, Martins C, Rodrigues A, et al. The effect of vitamin A supplementation administered with missing vaccines during national immunisation days in Guinea-Bissau. Int J Epidemiol. 2009;38:304-311.
11. Aaby P, Jensen H, Rodrigues A, et al. Divergent female-male mortality ratios associated with different routine vaccinations among female-male twin pairs. Int J Epidemiol. 2004;33:367-373.
12. Aaby P, Ibrahim S, Libman M, et al. The sequence of vaccinations and increased female mortality after high-titre measles vaccine: trials from rural Sudan and Kinshasa. Vaccine. 2006;24:2764-2771.
13. Aaby P, Jensen H, Samb B, et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet. 2003;361:2183-2188.
14. Aaby P, Jensen H, Gomes J, et al. The introduction of diphtheria-tetanus-pertussis vaccine and child mortality in rural Guinea-Bissau: an observational study. Int J Epidemiol. 2004;33:374-380.
15. World Health Organization. Conclusions and recommendations from the immunization strategic advisory group. Wkly Epidemiol Rec. 2006;81:2-11.
16. World Health Organization. Meeting of the immunization strategic advisory group of experts, November 2008\conclusions and recommendations. Wkly Epidemiol Rec. 2009;84:1-16.
17. Hesseling AC, Cotton MF, Marais BJ, et al. BCG and HIV reconsidered: moving the research agenda forward. Vaccine. 2007;25:6565-6568.
18. Moss WJ, Halsey NA. Vaccination of human immunodeficiency virus-infected persons. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 4th ed. Philadelphia, PA: Saunders; 2004:169-178.
19. Benn CS, Diness BR, Roth A, et al. Effect of 50000 IU vitamin A given with BCG vaccine on mortality in infants in Guinea-Bissau: randomised placebo controlled trial. BMJ. 2008;336:1416-1420.
20. Sajid MS, Iqbal Z, Muhammad G, et al. Effect of ivermectin on the cellular and humoral immune responses of rabbits. Life Sci. 2007;80:1966-1970.
21. Dvoroznakova E, Hrckova G, Boroskova Z, et al. Effect of treatment with free and liposomised albendazole on selected immunological parameters and cyst growth in mice infected with Echinococcus multilocularis. Para-sitol Int. 2004;53:315-325.
22. Maizels RM. Infections and allergy\helminthes, hygiene and host immune regulation. Curr Opin Immunol. 2005;17:656-661.
23. WHO. World health report 2005: make every mother and child count. Geneva, Switzerland: WHO. 2006;186-188.
24. Lawn JE, Cousens S, Zupan J; Lancet Neonatal Survival Steering Team. 4 million neonatal deaths: when? Where? Why? Lancet. 2005;365:891-900.
25. ten Dam HG, Hitze KL. Does BCG vaccination protect the newborn and young infants. Bull WHO. 1980;58:37-41.
26. Hussey GD, Watkins ML, Goddard EA, et al. Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies. Immunology. 2002;105:314-324.
27. Marchant A, Goetghebuer T, Ota M, et al. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J Immunol. 1999;163:2249-2255.
28. Ota M, Vekemans J, Schlegel S, et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol. 2002;168:919-925.
29. Kaur S, Faridi MM, Agarwal KN. BCG vaccination reaction in low birth weight infants. Indian J Med Res. 2002;116:64-69.
30. Roth A, Jensen H, Garly ML, et al. Low birth weight infants and Calmette-Guerin bacillus vaccination at birth: community study from Guinea-Bissau. Pediatr Infect Dis J. 2004;23:544-550.
31. Martins CL, Garly M-L, Bale C, et al. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. BMJ. 2008;337:a661.
32. Aprile MA, Wardlaw AC. Aluminium compounds as adjuvants for vaccines and toxoids in man: a review. Can J Public Health. 1966;57:343-354.
33. Fine PE, Williams TN, Aaby P, et al; Working Group on Non-specific Effects of Vaccines. Epidemiological studies of the 'non-specific effects' of vaccines: I\data collection in observational studies. Trop Med Int Health. 2009;14:969-976.
34. Farrington CP, Firth MJ, Moulton LH, et al; Working Group on Nonspecific Effects of Vaccines. Epidemiological studies of the non-specific effects of vaccines: II\methodological issues in the design and analysis of cohort studies. Trop Med Int Health. 2009;14:977-985.